title: Pneumoconiosis-related lung cancers: preferential occurrence from diffuse interstitial fibrosis-type pneumoconiosis.
abstract: It has been reported that patients with pneumoconiosis occasionally have a diffuse interstitial fibrosis (DIF) that resembles interstitial pneumonia, but little is known about the relation between pneumoconiosis-associated DIF and the risk of lung cancer. In the present study, we evaluated the incidence of DIF by chest CT and its contribution to lung cancer in 563 patients with nonasbestos pneumoconiosis. Fifty-five (10%) of the 563 patients had DIF. Pneumoconiosis with DIF had an exceedingly high concurrence of lung cancers when compared with pneumoconiosis without DIF (29 [53%] of 55 versus 78 [15%] of 508, p < 0.001). Squamous cell carcinomas (SCCs) of the lung from pneumoconiosis with DIF exclusively comprised peripheral-types, as compared with SCCs from pneumoconiosis without DIF (13 [100%] of 13 versus 33 [72%] of 46, p = 0.03). In addition, lung cancers arose frequently from the area of DIF in pneumoconiosis with DIF (20 [74%] of 27). Furthermore, our pathologic examination revealed that dysplasias from pneumoconiosis with DIF were significantly more frequently observed in peripheral bronchioli than were dysplasias from pneumoconiosis without DIF (11 [69%] of 16 versus 20 [30%] of 66, p = 0.01). p53 expression evaluated by immunohistochemistry was frequently observed in dysplasias from pneumoconiosis with DIF, although it was not significantly different compared with that in dysplasias from pneumoconiosis without DIF (5 [50%] of 10 versus 12 [38%] of 32). Taken together, these results may suggest a positive causal relationship between pneumoconiosis and peripheral-type SCCs of the lung, and further indicate a pivotal role of diffuse fibrosis for the excess incidence of lung cancers, especially peripheral-type SCCs, in DIF-type pneumoconiosis.
authors.affiliation: Iwamizawa Rosai Hospital, Iwamizawa, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Katabami
authors.forename: H
authors.initials: H
authors.lastname: Dosaka-Akita
authors.forename: K
authors.initials: K
authors.lastname: Honma
authors.forename: Y
authors.initials: Y
authors.lastname: Saitoh
authors.forename: K
authors.initials: K
authors.lastname: Kimura
authors.forename: Y
authors.initials: Y
authors.lastname: Uchida
authors.forename: H
authors.initials: H
authors.lastname: Mikami
authors.forename: Y
authors.initials: Y
authors.lastname: Ohsaki
authors.forename: Y
authors.initials: Y
authors.lastname: Kawakami
authors.forename: K
authors.initials: K
authors.lastname: Kikuchi
mesh_terms: D000368:Aged; D006801:Humans; D015994:Incidence; D017563:Lung Diseases, Interstitial / Q000150:complications* / Q000378:metabolism / Q000473:pathology; D008175:Lung Neoplasms / Q000453:epidemiology* / Q000209:etiology* / Q000378:metabolism / Q000473:pathology; D011009:Pneumoconiosis / Q000150:complications* / Q000378:metabolism / Q000473:pathology; D011658:Pulmonary Fibrosis / Q000150:complications* / Q000378:metabolism / Q000473:pathology; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000096:biosynthesis
chemical_list: D016159:Tumor Suppressor Protein p53